Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Data is available to registered users only
Buy
Sell